habits of the host, as a vegan subject did not produce any TMAO after an l-carnitine challenge test.
It has been demonstrated that the gut microbiota can adapt to its host's dietary preferences by acquiring genes that are essential for processing specific macronutrients through horizontal gene transfer. The gut microbiomes of Japanese individuals who consume large amounts of seaweed acquire genes encoding porphyranases and agarases from marine bacteria that populate seaweed, which may facilitate degradation and use of algal polysaccharides 10 . These findings further emphasize that the gut microbiome is 'plastic' and can adapt to the host's diet. However, it is unclear how rapidly a vegan will begin to metabolize l-carnitine once switched to an omnivorous diet and, conversely, how soon this capacity will be lost once an omnivorous subject stops eating meat, and this will need to be investigated in further studies.
To examine the mechanisms by which microbial metabolism of l-carnitine contributes to CVD, Koeth et al. 9 carried out parallel experiments in mice and demonstrated that after oral carnitine challenge neither germfree mice nor mice that were treated with antibiotics produced TMAO. The authors then fed atherosclerosis-prone Apoe −/− mice a diet supplemented with l-carnitine, which significantly increased atherosclerotic plaque burden. This increase was abrogated when the Apoe −/− mice were treated with antibiotics, demonstrating a direct link between microbial production of TMAO and atherosclerosis, the underlying cause of most CVDs. Furthermore, the authors showed that TMAO inhibits reverse cholesterol transport and also reduces bile acid synthesis, both of which are associated with increased atherosclerosis.
In this study, Koeth et al. 9 have illustrated the importance of taking a translational approach to dissecting the molecular mechanisms by which the gut microbiota contributes to CVD by combining well-phenotyped patients and mouse models. Their data indicate that the gut microbiota adapts to an omnivorous diet and metabolizes carnitine into TMA and TMAO, metabolites that are associated with CVD in humans and have been shown to directly cause atherosclerosis in mice 7 . However, the exact mechanisms by which TMAO affects reverse cholesterol transport and bile acid synthesis remain elusive, and it is unclear whether TMAO binds a receptor or whether it may have direct effects on enzymes in these pathways.
The identification of the bacterial taxa that produce TMAO and that correlate with CVD may yield potential biomarkers for treating this disease. Furthermore, inhibitors of microbial conversion of choline and l-carnitine into TMA may be new weapons for the treatment or prevention of CVD. Although more studies are needed, the findings of Koeth et al. 9 suggest that further work delineating the interactions between the gut microbiota and specific macronutrients may reveal underlying mechanisms for how the gut microbiota contributes to metabolic diseases. One such recent example is the use of 'personalized gnotobiotics' , where germ-free mice are colonized with feces from well-phenotyped human subjects 11 and subsequently fed specific diets to demonstrate that the altered microbiota can directly transfer the phenotype observed in the original human host. Using this strategy, Gordon and his colleagues 12 elegantly demonstrated that the gut microbiota is altered in malnourished children compared with their well-nourished, healthy twin siblings and that the altered microbial ecology contributes to weight loss in mice fed a typical Malawian diet. Thus, the gut microbiota is emerging as an important environmental factor to consider in human nutrition and metabolism. and inhibit sodium ion reabsorption that results in natriuresis, respectively. GC-A is also highly expressed in the adrenal glands, where ANP inhibits the production and release of aldosterone, which contributes to blood pre ssure reduction. ANP seems to function as a key physiologic regulator of blood pressure homeostasis through these pleiotropic actions. Recently, genetic variants of the ANP gene (NPPA) that result in an increase in circulating levels of ANP have been associated with low blood pressure, decreased risk of hypertension The heart plays a fundamental part in blood pressure regulation through the production and release of the peptide hormone atrial natriuretic peptide (ANP) 1 . ANP is synthesized as a prohormone in secretory granules of cardiomyocytes located in the atria of the heart, and the prohormone is processed into the mature, biologically active ANP that functions via guanylyl cyclase A (GC-A) to then produce the second messenger 3′,5′-cyclic guanosine monophosphate (cGMP) 2 
A gut-heart connection in cardiometabolic regulation

Alessia Buglioni & John C Burnett Jr
A new study establishes a link between glucagon-like peptide-1 (GLP-1) release from the gut and the cardiac hormone atrial natriuretic peptide, which lowers blood pressure. As GLP-1 receptor agonists are used to control glycemia in patients with type 2 diabetes, this new gut-heart axis suggests a role of these agents in overall cardiovascular homeostasis (pages 567-575). npg and protection from the metabolic syndrome in the general population 3, 4 .
In the current issue of Nature Medicine, Kim et al. 5 provide an entirely new mechanism in the control of ANP release from the heart by a gut-released hormone, thus revealing a new gut-heart connection in the control of blood pressure. Previously, patients with diabetes receiving long-acting GLP-1 agonists, including liraglutide and exenatide, showed a reduction in blood pressure 6 . The authors used normotensive mice and two mouse models of hypertension to show that the effect of liraglutide may be linked to ANP and GLP-1 receptors (GLP-1R) in the atria. This study changes our view of the physiology of ANP and the molecular mechanisms mediating its release from atrial cardiomyocytes. Clinically, the findings further our understanding of how long-acting GLP-1 agonists, widely used in T2D, may exert a beneficial effect in this disease, which is associated with high cardiovascular risk and often occurs in the setting of hypertension.
Liraglutide belongs to the new therapeutic group of mimetics of incretins-gut-released hormones that include GLP-1-which are currently used in T2D given their potential cardio protective and blood pressure-lowering effects 6 . In normotensive and hypertensive mice, the cardiac localization of the GLP-1R, previously shown without chamber-specific localization in the human heart, was limited to atria 5 . Notably, after food intake, liraglutide and GLP-1 induced ANP secretion from atrial cardiomyocytes through GLP-1R. After subcutaneous infusion of angiotensin II to induce hypertension, liraglutide treatment did not lower blood pressure in mice lacking GLP-1R, whereas in wild-type mice blood pressure was substantially reduced after treatment. The vasodilatory effects of liraglutide on blood vessels did not seem to be direct and were not mediated by the vasodilator acetylcholine, which functions through nitric oxide signaling in the endothelium; instead, a vasodilatory response was observed on the inner surface of vessels, indicating a vascular smooth muscle relaxation after GLP-1R activation, also independent of nitric oxide 5 .
In normotensive and hypertensive Nppadeficient mice, liraglutide failed to reduce blood pressure and did not increase urine sodium excretion, indicating an indirect ANPdependent effect 5 . The ANP secretion from atrial cardiomyocytes induced by liraglutide activation of GLP-1R was mediated by activation of the downstream effector Epac2 in both normotensive and hypertensive mice, as mice with germline deletion of the Epac2 gene (Rapgef4) did not show increased plasma ANP levels after GLP-1R agonist infusion. Liraglutide is thus an ANP secretagogue that releases the hormone via a GLP-1R/Epac2 signaling pathway mechanism that leads to vasodilation and natriuresis. Liraglutide did not increase plasma concentrations of a ventricular hormone that exerts similar blood pressure functions to ANP 5 .
The study by Kim et al. 5 raises some intriguing questions. In vivo injection of native GLP-1 only modestly increased ANP abundance, indicating that it may be rapidly degraded 5 . However, after a meal, plasma ANP levels increased after 10 min in wild-type mice, but not in GLP-1R-deficient mice. What is the exact molecular form of native GLP-1 released after a meal? Could it be more resistant to enzymatic degradation? Acute administration of liraglutide in normotensive and hypertensive mice increased ANP levels and lowered blood pressure, and sustained administration twice per day for 3 weeks in angiotensin II-infused mice continued to induce the same effects, mostly during the evening lights-off period. This is of clinical significance, as it indicates that the blood pressure-lowering action of liraglutide may be long lasting. As hypertension is frequent in individuals with diabetes, long-acting GLP-1 agonists could also reduce blood pressure in these individuals, especially during nighttime, when the reductions in blood pressure achieved by these agonists are greater. It would be very interesting to investigate whether other GLP-1R agonists, such as exenatide, may also efficiently activate the same pathway. Further, it will be important to determine whether the liraglutide actions continue beyond the period reported in the current study.
As we search for the physiological meaning of this gut-heart axis, it could be speculated that the vasodilatory response after GLP-1R activation, secondary to ANP release, promotes an increased blood supply to target organs including the gut, pancreas, kidney Katie Vicari Figure 1 Cardiometabolic actions of GLP-1 and GLP-1 agonists through activation of atrial ANP secretion. Nutrients from meals are absorbed by the ileum followed by release of GLP-1 from secretory vesicles in ileum epithelial cells. In the pancreas, GLP-1 reduces glucagon secretion and increases insulin release via GLP-1R to regulate optimal glucose homeostasis. GLP-1 activates GLP-1Rs in the atrial myocardium, which induces ANP secretion from atrial secretory granules; this action is mimicked by the long-acting GLP-1 agonist liraglutide via activation of Epac2, which stimulates secretion of ANP. ANP mediates pleotropic actions via the GC-A/cGMP signaling pathway to reduce blood pressure by augmenting endothelial permeability, inducing vascular smooth muscle relaxation, enhancing sodium excretion and inhibiting sodium ion reabsorption in the kidney. ANP may also improve metabolic homeostasis through activating lipolysis and energy use in adipocytes, resulting in increased energy expenditure.
GLP-1R
GLP-1 agonists to gain the benefit of this link to the heart and ANP, should future clinical studies support preclinical findings. Clearly, we are entering an exciting period in which new therapeutics with widespread pleiotrophic properties modulating a number of endocrine systems will be the focus of continuing basic clinical research.
inhibition of renin and suppression of aldosterone secretion. With the increase in diabetes worldwide, it is reassuring to know that the antidiabetic drug liraglutide has pleiotrophic actions-beyond the increase in insulin release and decrease in glucagon secretion-that now include a link to the heart and the release of the blood pressure-lowering and natriuretic peptide ANP. One could also predict possible beneficial effects of liraglutide in the improvement in insulin sensitivity independent from the direct insulin secretory effects, reduction in salt sensitivity, reduction in cardiac and renal injury and fibrosis, and increase in lipolysis, thermogenesis and energy expenditure with secondary weight loss. The findings of the study hint at the 'wisdom of the body' wherein an increase in nutrients after a meal translates into gut-mediated homeostasis 10 . Now, the link from the gut to the pancreas can include a gut-heart connection, which goes beyond merely blood pressure regulation, as ANP also regulates important metabolic actions such as lipolysis, lipid oxidation, enhanced thermogenesis and modulation of insulin release 11, 12 (Fig. 1) . Indeed, physicians caring for patients with diabetes, particularly those with hypertension and/ or metabolic syndrome, may begin to even personalize therapy with long-acting GLP-1R and adipose tissue. This vascular response could result in better absorption and distribution of nutrients, optimized renal handling of sodium so as to regulate intravascular volume, and effective regulation of insulin and glucagon release (Fig. 1) .
Subjects with T2D are often overweight or obese, hypertensive and dyslipidemic and also show metabolic syndrome featuresconditions characterized by lower natriuretic peptide levels and overactivation of the reninangiotensin-aldosterone system, which may contribute to hypertension 7, 8 . As the authors used two models of hypertension-secondary to subcutaneous infusion of angiotensin II and hypertension produced by aortic constriction, the action on ANP release by liraglutide may suggest that the probability of translating these findings to human hypertension is high. Thus, it will be important to analyze the liraglutide effect in humans in the context of T2D along with these comorbidities to verify whether these actions persist.
The authors have clearly advanced our understanding of therapeutics related to both diabetes and hypertension and have provided insights into a new endocrine axis between the gut and the heart, which then links to the kidney, where ANP mediates natriuresis 9 through increases in glomerular filtration rate, direct during EAE pathogenesis. Peli1 regulates a new Toll-like receptor (TLR) signaling pathway via ubiquitin-dependent degradation of an inhibitor of mitogen-activated protein kinase (MAPK) signaling downstream of TLRs called tumor necrosis factor receptor-associated factor 3 (Traf3), resulting in activation of inflammatory factors that trigger recruitment of inflammatory cells in the CNS. The work shows a new microglia-specific mediator of neuroinflammation in multiple sclerosis.
Microbial infections have long been considered to contribute to the onset of multiple sclerosis 1 , and in EAE, disease is induced by an adjuvant containing inactivated bacteria together with autoantigen. Signaling by TLRs, which are pattern recognition receptors responsible for detecting microbial products, has been shown to Multiple sclerosis is an autoimmune inflammatory disease of the central nervous system (CNS) that results in loss of body sensitivity, muscle weakness and spasms, and difficulties in moving, speech or swallowing. In the preclinical setting, experimental autoimmune encephalomyelitis (EAE) is a well-recognized animal model for human multiple sclerosis that recapitulates the myelin autoantigen-driven chronic inflammation found in the focal areas of the CNS of people with multiple sclerosis that results in demyelination and, consequently, axon loss 1 . Microglia are local resident innate immune cells populated early in the CNS during fetal development, whose activation induces inflammatory factors such as cytokines and chemokines to recruit inflammatory immune cells to the CNS. Microglia also function as local antigen-presenting cells to reactivate T cells recruited to the CNS, thereby contributing to the inflammatory pathogenesis of multiple sclerosis and EAE 2 . However, the molecular mechanisms of microglia activation still remain elusive.
In this issue of Nature Medicine, Xiao et al. 3 
Peli1 sets the CNS on fire
Xinyang Song & Youcun Qian
It has long been unknown how activation of resident macrophages in the brain, or microglia, is regulated during the inflammatory pathogenesis of multiple sclerosis. Work in a mouse model of human multiple sclerosis identifies the E3 ubiquitin ligase Peli1 as a new crucial regulator of microglia activation (pages 595-602).
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